Lysophosphatidic Acid 18:0 sn-1 in Cerebrospinal Fluid as a Potential Biomarker of Depressive Symptoms in Patients with Neuropathic Pain
Authors:
- Reo InoueRIReo Inoue
- Masahiko SumitaniMSMasahiko Sumitani
- Atsushi KimuraAKAtsushi Kimura
- Takao MochizukiTMTakao Mochizuki
- Toru AkiyamaTAToru Akiyama
- Yoshifumi MoritaYMYoshifumi Morita
- Takuya TakahashiTTTakuya Takahashi
- Takashi HiraiTHTakashi Hirai
- Kentaro HayakawaKHKentaro Hayakawa
- Hirotaka ChikudaHCHirotaka Chikuda
- Makoto KuranoMKMakoto Kurano
Open Access
- 28 May 2026
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 16 (6) , 573
Abstract
Background/Objectives: Lysophosphatidic acid (LPA) is a bioactive lipid mediator implicated in neuropathic pain (NP). Depressive symptoms frequently accompany NP and adversely affect outcomes, yet objective biomarkers remain limited. This study aimed to identify cerebrospinal fluid (CSF) LPA molecular species associated with depressive symptoms in patients with NP. Methods: CSF samples were obtained from 48 patients, and LPA species, including positional isomers (sn-1 and sn-2), were quantified using liquid chromatography–tandem mass spectrometry. Depressive symptoms were assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Statistical analyses were performed to evaluate associations among depressive symptoms, clinical variables, and LPA species. Results: CSF LPA18:0 was significantly associated with HADS-D scores (r = 0.380, p = 0.010), with the strongest association observed for the sn-1 isoform (r = 0.385, p = 0.009). In multivariable analysis, LPA18:0 sn-1 remained independently associated with depressive symptoms, alongside pain intensity and pain catastrophizing (R2 = 0.386). Structural equation modeling supported an association between LPA18:0 sn-1 and depressive symptoms independent of pain-related factors. Conclusions: These findings suggest that CSF LPA18:0 sn-1 may be associated with a biological dimension of depressive distress and may represent a candidate biomarker of depressive distress in NP. However, these findings should be interpreted cautiously, as the analyses were exploratory, and further validation in independent and longitudinal cohorts is warranted.Keywords
Funding Information
- Japan Agency for Medical Research and Development (22ek0610028h0001)
- Japan Agency for Medical Research and Development (19lm0203084h001)
This publication has 25 references indexed in Scilit:
- Different Profiles of the Triad of Lysophosphatidylcholine, Lysophosphatidic Acid, and Autotaxin in Patients with Neuropathic Pain Diseases: a Preliminary Observational StudyPain and Therapy, 2022
- Reduced neuroinflammation and enhanced neurogenesis following chronic agomelatine treatment in rats undergoing chronic constant lightNeuropharmacology, 2021
- Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesisProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2021
- Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditionsMolecular Psychiatry, 2016
- Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosisPsychiatry Research, 2014
- Lysophospholipids and their receptors in the central nervous systemBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013
- Lysophosphatidic acid: Chemical signature of neuropathic painBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013
- Initiation of neuropathic pain requires lysophosphatidic acid receptor signalingNature Medicine, 2004
- LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric diseaseMolecular and Cellular Neuroscience, 2003
- The Pain Catastrophizing Scale: Development and validation.Psychological Assessment, 1995